ArticleResearch square2023
Advancing Tau-PET quantification in Alzheimer's disease with machine learning: introducing THETA, a novel tau summary measure.
Robel K Gebre, Alexis Moscoso Rial, Sheelakumari Raghavan, Heather J Wiste, Kohl L Johnson Sparrman, Fiona Heeman, Alejandro Costoya-Sánchez, Christopher G Schwarz, Anthony J Spychalla, Val J Lowe and 7 more
Abstract readPreprint
In one paragraphArticle in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
17 authors.
Alexis Moscoso RialDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0003-0170-036X Sheelakumari RaghavanDepartment of Radiology, Mayo Clinic, Rochester, MN 55905, USA.
Heather J WisteDepartment of Qualitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Kohl L Johnson SparrmanDepartment of Radiology, Mayo Clinic, Rochester, MN 55905, USA.
Fiona HeemanDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Alejandro Costoya-SánchezUniversidade de Santiago de Compostela, Santiago de Compostela, Spain.
Anthony J SpychallaDepartment of Radiology, Mayo Clinic, Rochester, MN 55905, USA.
Val J LoweDepartment of Radiology, Mayo Clinic, Rochester, MN 55905, USA.
Jonathan Graff-RadfordDepartment of Neurology, Mayo Clinic, Rochester, MN 55905, USA.
Michael SchöllDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0001-7800-1781 Alzheimer’s Disease Neuroimaging Initiative
Funding
Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0MSmartphone-Based "Burst" Cognitive AssessmentsP01AG003991 · NIA · WASHINGTON UNIVERSITY · PI JOHN MORRIS · 1985 to 2026
$69.5MSUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6MThe natural history of AB accumulation in preclinical ADP01AG026276 · NIA · WASHINGTON UNIVERSITY · PI SCHINDLER, SUZANNE ELIZABETH · 2005 to 2025
$49.5MWashington University Institute of Clinical and Translational SciencesUL1TR000448 · NCATS · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2012 to 2016
$41.4MTHE PGRN/TDP-43 AXIS IN ALZHEIMER?S DISEASE AND NEURODEGENERATIONP50AG016574 · NIA · MAYO CLINIC ROCHESTER · PI BU, GUOJUN · 1999 to 2018
$36.9MResearch Education ComponentP30AG066444 · NIA · WASHINGTON UNIVERSITY · PI DAVID M. HOLTZMAN · 2020 to 2026
$28.7MTHE XNAT IMAGING INFORMATICS PLATFORMR01EB009352 · NIBIB · WASHINGTON UNIVERSITY · PI Daniel Scott Marcus · 2009 to 2026
$9.3MInvestigating Resistance and Resilience Mechanisms in Alzheimer’s DiseaseR01AG056366 · NIA · MAYO CLINIC ROCHESTER · PI PRASHANTHI VEMURI · 2017 to 2026
$7.0MDisease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkersR37AG011378 · NIA · MAYO CLINIC ROCHESTER · PI CLIFFORD R. JACK · 2018 to 2026
$6.8MValidating the New Criteria for Preclinical Alzheimer's diseaseR01AG041851 · NIA · MAYO CLINIC ROCHESTER · PI JACK, CLIFFORD R., KNOPMAN, DAVID S · 2012 to 2021
$6.3MMarkVCID Validation in the General CommunityUF1NS125417 · NINDS · MAYO CLINIC ROCHESTER · PI PETERSEN, RONALD C, VEMURI, PRASHANTHI · 2021 to 2023
$6.1MNCATS NIH HHS UL1 TR000448NCRR NIH HHS C06 RR018898NIA NIH HHS P01 AG003991NIA NIH HHS P01 AG026276NIA NIH HHS P30 AG066444NIA NIH HHS P50 AG016574NIA NIH HHS R01 AG041851NIA NIH HHS R01 AG043434NIA NIH HHS R01 AG056366NIA NIH HHS R21 AG058738NIA NIH HHS R33 AG058738NIA NIH HHS R37 AG011378NIA NIH HHS RF1 AG069052NIA NIH HHS U01 AG006786NIA NIH HHS U01 AG024904NIBIB NIH HHS R01 EB009352NINDS NIH HHS R01 NS097495NINDS NIH HHS UF1 NS125417
6 · The paper itselfAbstract
Alzheimer's disease (AD) exhibits spatially heterogeneous 3R/4R tau pathology distributions across participants, making it a challenge to quantify extent of tau deposition. Utilizing Tau-PET from three independent cohorts, we trained and validated a machine learning model to identify visually positive Tau-PET scans from regional SUVR values and developed a novel summary measure, THETA, that accounts for heterogeneity in tau deposition. The model for identification of tau positivity achieved a balanced test accuracy of 95% and accuracy of ≥87% on the validation datasets. THETA captured heterogeneity of tau deposition, had better association with clinical measures, and corresponded better with visual assessments in comparison with the temporal meta-region-of-interest Tau-PET quantification methods. Our novel approach aids in identification of positive Tau-PET scans and provides a quantitative summary measure, THETA, that effectively captures the heterogeneous tau deposition seen in AD. The application of THETA for quantifying Tau-PET in AD exhibits great potential.
Identifiers
PMID37886506
PMCPMC10602128
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390